Chronic hepatitis B (CHB) is a major cause of liver disease worldwide despite the availability of effective vaccination. There are still more than 350 million people chronically infected with the hepatitis B virus (HBV)1 and progression of HBV-related liver inflammation to cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC) is estimated to result in up to 1.2 million deaths annually.

, , , ,
Printing of this thesis was supported by F. Hoffmann-La Roche, Erasmus Universiteit Rotterdam, the department of Gastroenterology and Hepatology of the Erasmus MC Rotterdam, Nederlandse Vereniging voor Hepatologie, J.E. Jurriaanse Stichting, Merck, Sharp & Dohme B.V., Gilead Sciences, Innogenetics, Abbott, Boehringer Ingelheim BV and Virology Education B.V.
H.L.A. Janssen (Harry)
Erasmus University Rotterdam
hdl.handle.net/1765/39715
Erasmus MC: University Medical Center Rotterdam

Sonneveld, M. (2013, April 19). Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B . Retrieved from http://hdl.handle.net/1765/39715